



ARISE Members and Partners Profiles

FY 2025

ARISE加盟施設リスト 2025年度版

ARISE加盟施設

1. [インドネシア大学\(FMUI・インドネシア\)](#)
2. [モフタル・リアディ・インスティテュート・フォー・ナノテクノロジー\(MRIN・インドネシア\)](#)
3. [クリニカル・リサーチ・マレーシア\(CRM・マレーシア\)](#)
4. [マラヤ大学医療センター\(UMMC・マレーシア\)](#)
5. [マヒドン大学医学部・シリラート病院\(SIRIRAJ・タイ\)](#)
6. [コラソン・ロクシン・モンテリバノ記念地域病院\(CLMMRH・フィリピン\)](#)
7. [フィリピン大学マニラ校\(UPM・フィリピン\)](#)
8. [ウェストビサヤ州立大学\(WVSU・フィリピン\)](#)
9. [国立バクマイ病院\(BMH・ベトナム\)](#)
10. [ハノイ医科大学\(HMU・ベトナム\)](#)
11. [ホーチミン 大学医療センター\(UMC・ベトナム\)](#)

Faculty of Medicine University of Indonesia

Jakarta, Indonesia



Faculty of Medicine University of Indonesia (FMUI) was established in 1950.

The faculty has a teaching hospital, type A hospital, located in Depok (40 km from Jakarta), ~372 beds

It is connected with 4 national center hospitals including cancer center, brain center, heart center, and infectious diseases center and 3 type A national hospitals within their Academic Health System (AHS).

UI Ethic Committee is accredited by FERCAP (Forum for Ethical Review Committees in the Asian and Western Pacific Region).

CRSU: Clinical Research Supporting Unit

CRSU is a contract research organization (CRO) a business unit under the Faculty of Medicine University of Indonesia. It started since 1990s.

■ Research personnel

- 5-10 Investigators
- 3 Study coordinators
- 2 CRAs

■ Infrastructures

- The office location is in a research building separated from hospital
- It has a dedicated clinical trial facility
- IT services
- Record, Investigational Product and Sample storage
- Power back-up
- Electronic Medical Record

Infectious Diseases Clinical Trials achievements and collaborations

Types of interventions (2019-2023)

	2019	2020	2021	2022	2023
Vaccines	1	0	2	5	0
Drugs	1	2	2	1	2
Diagnostic test	0	1	0	0	0

Trials by Phases (2019-2023)

	Phase1	Phase1/2	Phase2	Phase2/3	Phase3	Phase4
2019	0	0	0	0	1	0
2020	1	0	0	0	1	0
2021	1	0	3	0	0	0
2022	1	0	1	0	4	0
2023	1	0	0	0	0	0

Trials by infectious diseases (2019-2023)

Diseases	Number of studies
COVID-19	8
Urinary track infection	2
Malaria	2
Bacterial infection	2
Typhoid	1

Trials

- The facility has been inspected by the National Regulatory authority (BPOM)
- Drug studies including drug for Malaria, Tuberculosis, and Urinary Track Infections.
- Past trials collaboration with Japanese institutes with Showa University for infectious diseases study and Otsuka for asthma study.
- Study phases ranging from phase 1-3.
- Ethical Review: 1-2 months (can be in parallel with clinical trial application)
- Clinical trial application: 3-6 months
- Import license: 1-12 month (can be in parallel with CT application)

Sample of trials manuscripts

- Tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure of *Plasmodium vivax* malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study. *Lancet Infect Dis.* 2023;23(10):1153-1163.
- Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19. *J Clin Med.* 2022 May 24;11(11):2961.
- An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia. *PLoS Negl Trop Dis.* 2021 Mar 29;15(3):e0009294.

Contact Information

Representative



Prof. Dr. Wawaimuli Arozal

Professor at the Department of Pharmacology and Therapeutic, Faculty of Medicine, University of Indonesia (FMUI).

Coordinator of Graduate Study Program, FMUI.

Former Head of the Department of Pharmacology and Therapeutic.

Focal Point

Prof. Dr. Melva Louisa

Professor at the Department of Pharmacology and Therapeutic, Faculty of Medicine, University of Indonesia (FMUI) CRSU, FMUI

ARISE Secretariat

Email: arise@jih.s.go.jp

Other Investigator

Dr. Anggi Gayatri

Address and Access Map

Department of Pharmacology and Therapeutic, Faculty of Medicine, University of Indonesia

Jl. Salemba Raya No.6, Kenari, Central Jakarta, Jakarta 10430 Indonesia



Mochtar Riady Institute for Nanotechnology

Siloam Hospitals Group

Tangerang, Indonesia



Mochtar Riady Institute for Nanotechnology (MRIN) and Siloam Hospital Groups (SHG) are private organizations owned by the Lippo Group in Indonesia.

MRIN aims to conduct innovative clinical research using genomic and proteomic approach.


SHG is the largest private hospital network in Indonesia. It has more than 41 hospitals branch and 25 clinics, serving ~3 million patients annually in 28 cities across Indonesia.

The two organizations are affiliated with Faculty of Medicine Universitas Pelita Harapan

MRIN Ethic Committee is accredited by FERCAP (Forum for Ethical Review Committees in the Asian and Western Pacific Region).

CRS: Clinical Research Siloam

Clinical Research Siloam responsible for clinical research support in SHG. The unit is established in 2021, with the support of JIHS (formerly known as NCGM).



Research personnel

- 3 Investigators for Infectious diseases
- 8 Clinical Research Coordinators
- 4 CRAs

Infrastructures

- The office location is in Tangerang
- It has its own office and a dedicated clinical trial facility at Siloam Hospitals
- Record, Investigational Product and Sample storage
- Power back-up in some of the big hospitals
- Electronic Medical Record

Infectious Diseases Clinical Trials achievements and collaborations (2021-2025)

Types of sponsors

- Investigators Initiated Trials: 1
- Industry Sponsored Trials: 8

On going studies

- Non-ID: 5
- ID: 0

Trials by infectious diseases

- Covid-19: 1

Trials

- MRIN/Siloam has experienced in Covid-19, Dengue, Hep B, and hep C studies.
- Past trials collaboration with Japanese institutes with Eiken, Taisho Pharmaceuticals.
- Has been inspected by the National Regulatory Authority (BPOM)
- Previous studies are mostly observational studies. Clinical trial studies started since 2021.
- Ethical Review: 1-2 months (can be in parallel with clinical trial application)
- Clinical trial application: 20 Weekdays (after protocol assessment is completed)
- Import license: 1 month (can be in parallel with CT application)

Sample of manuscripts

- Oktavianthi S, Lages AC, Kusuma R, Kurniasih TS, Trimarsanto H, Andriani F, Rustandi D, Meriyanti T, Yusuf I, Malik SG, Jo J, Suriapranata I. Whole-Genome Sequencing and Mutation Analyses of SARS-CoV-2 Isolates from Indonesia. *Pathogens*. 2024 Mar 25;13(4):279.
- Santi T, Sungono V, Kamarga L, Samakto B, Hidayat F, Hidayat FK, Satolom M, Permana A, Yusuf I, Suriapranata IM, Jo J. Heterologous prime-boost with the mRNA-1273 vaccine among CoronaVac-vaccinated healthcare workers in Indonesia. *Clin Exp Vaccine Res*. 2022 May;11(2):209-216.
- Widysanto A, Prasetya IB, Meriyanti T, Sungono V, Setiawan DL, Gunawan E, Adiputra B, Lorens JO, Santi T, Pradhana CML, Yusuf I, Gunawan C. The risk factors of SARS-CoV-2 antibody level differences in healthcare workers post vaccination in Siloam hospitals: A nationwide multicenter study. *Infect Med (Beijing)*. 2022 Dec;1(4):229-235.

Contact Information

Representatives



Prof. Dr. Irawan Yusuf

President of MRIN. Advisory Board of MRIN.

He is one of the Key Opinion Leaders (KOLs) for clinical research in Indonesia. In the field of infectious diseases he chaired international research initiative focusing on tuberculosis and dengue between Novartis and Indonesia.

Focal Point



Dr. Juandy Jo

Executive Director
Mochtar Riady Institute for Nanotechnology



Dr. Jane Olivia Lorens

Head of Clinical Research Department
Clinical Research Siloam

ARISE Secretariat

Email: arise@jih.go.jp


Other Investigator

- Dr. Ivet Marita Suriapranata, Molecular Biologist
- Prof. Dr. Cucunawangsih, Infectious Disease Specialist

Address and Access Map

Mochtar Riady Institute for Nanotechnology/ Siloam Hospitals Lippo-Karawaci, Clinical Research Siloam Office are located in the same area.

No. 6 Jl. Siloam Lippo Karawaci 15810 Kelapa Dua Banten, Indonesia



Clinical Research Malaysia

Kuala Lumpur, Malaysia




CRM, a company fully owned by the Ministry of Health, was established in June 2012. Its headquarters is located in Kuala Lumpur, and have received the ISO 9001:2015 (QMS) and ISO 37001:2016 (Anti-Bribery Management System).

CRM has been a self-sufficient organisation since 2019 and serves not only as a one-stop centre for sponsored research in the country, but also as a Site Management Organization for the Ministry of Health trial sites.

CRM is affiliated with 57 Hospitals in Malaysia, both in public and academic.

CRM provides complimentary feasibility outreach to all sites in Malaysia (including in the public, university hospital and private hospitals). To date, over 300 sites throughout Malaysia have experience in sponsored research.

Management of CRM



Research personnel

- 32 Investigators for Infectious Diseases
- 214 Study Coordinators

Infrastructures

- Dedicated trial facilities are available at the hospitals
- Some sites use Electronic Medical Record (EMR)

Infectious Diseases Clinical Trials achievements and collaborations (past three years)

Types of interventions

- ID drug/Biologics/devices development: 25
- Non-ID drug/Biologics/ Devices development: 475
- Industry Sponsored Trials: 500

Trials by Phases

- Phase II: 6 Studies
- Phase III: 8 Studies
- Phase IV: 2 Studies

Trials by infectious diseases

Influenza	HIV	Blood Stream Infections
Covid-19	Zika	Ventilator Associated Pneumonia
Hepatitis	Tuberculosis	<i>S. Aureus</i>
Respiratory Syncytial Virus	<i>E.Coli</i>	Nipah
Dengue	Malaria	Antimicrobial Resistance/ Stewardship

Ongoing trials

- Ongoing ID Trials : 24 Studies

Trials

- CRM was involved in global/multi-country studies:
 1. A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications (NCT05568706)
 2. Study of AT-752 in Patients With Dengue Infection (NCT05466240)
- Investigators in Malaysia have been recognized as global top 3 recruiters, as well as global and regional first recruiters for a spectrum of clinical trials conducted in Malaysia.
- Past trials collaborations with Japanese industries were with Taiho, Otsuka, Takeda, Terumo, CMIC, Sumitomo Dainippon, Mitsubishi Tanabe, Chugai, University of Tokyo, Kyoto University, Matsutani Chemical Industry, Nagasaki University, Santen Pharma, Osaka University, National Cancer Center Japan
- CRM has received inspection by the USFDA
- Ethical Review: 32 Working Days (WD)
- Clinical trial application: 30-45 WD
- Import license: 30-45 WD

Contact Information

Representative



Asha Thanabalan

Lead of Business Development,
Clinical Research Malaysia

Asha has been with Clinical Research Malaysia (CRM) since November 2012, bringing over 13 years of experience in the clinical research ecosystem, including in research ethics. In her current role, she leads the feasibility, business relations and corporate communications team, providing country/ site insights on trial capabilities as well as leading multi-stakeholder engagements, strategic collaborations, and promotional initiatives to strengthen Malaysia's clinical research positioning. Asha also leads the ASEAN clinical research initiative aimed at advancing regional collaboration in industry-sponsored clinical research.

Focal Point


ARISE Secretariat

Email: arise@jih.go.jp

Address and Access Map

Clinical Research Malaysia

No. 2, Jalan Kerinchi Gerbang Kerinchi Lestari 59200
Kuala Lumpur Kuala Lumpur, Malaysia



Universiti Malaya Medical Centre



Kuala Lumpur, Malaysia



- Establish in 1968
- Located in Pantai Dalam, southwest corner of Kuala Lumpur, Malaysia
- 1800 beds, 5 ICU
- Laboratories accredited under Skim Akreditasi Makmal Malaysia (SAMM), meet the requirements of ISO 15189

UMMC is in a clinical trial network with Clinical Research Malaysia (CRM), Ministry of Health Malaysia hospitals (e.g., Hospital Kuala Lumpur), Ministry of Higher Education Malaysia hospitals (e.g., Hospital Canselor Tuanku Muhriz)

Management of CRM



■ Research personnel

- 10 PIs in IDs
- 81 Clinical Research Coordinators

■ Infrastructures

- Dedicated trial facilities are available at the hospitals
- Secured records storage facility
- Investigational Product storage
- Samples storage
- Power back up system
- Data Management system
- IT Services
- EMR system is implemented
- Lab processing, Consultation Room, Monitoring Room

Infectious Diseases Clinical Trials achievements and collaborations (2021-2025)

Types of interventions

- ID drug/Biologics/devices development: 4
- Non-ID drug/Biologics/ Devices development: 5
- Investigators Initiated Trials: 7
- Industry Sponsored Trials: 2

Trials by Phases

- Phase 3 trials for ID: 2

Trials by infectious diseases

- Influenza
- Covid-19
- Hepatitis
- Respiratory syncytial virus
- Dengue
- HIV
- Tuberculosis

Ongoing trials

- ID: 13
- Non-ID: 287

Trials

- Most of Clinical Trials by UMMC are on non-infectious diseases. However, UMMC has been involved in global/multi-country studies such: SNAP Trial (Collaboration with Tan Tock Seng Hospital, Singapore); INVEST Trial (Singapore Infectious Disease Clinical Research Network)
- UMMC has had collaborations with Japanese pharmaceutical: Daiichi Sankyo Co., Ltd.
- The facility has received inspections from the national regulatory authority (NPRA)
- Outstanding achievement:
 - Study Site of the Year by Clinical Research Malaysia
 - Top Recruiter Worldwide
 - First Patient Recruited Worldwide
- Ethical Review: 2 months
- Clinical trial application: 3-5 months
- Import license: 1-2 months

Contact Information

Representative



Dr. Lim Soo KUN

Professor and Senior Consultant
Nephrologist
Renal Division, Department of
Medicine

University Malaya Medical Center
(UMMC), Malaysia

Focal Point



Ms. Zulaikha Syazwani Zulkifly


ARISE Secretariat
Email: arise@jih.s.go.jp

Other Investigator

1. Prof. Sasheela Sri La Sri Ponnampalavanar,
Antibiotic resistance
2. Dr. Rong Xiang Ng, Infectious diseases
specialist

Address and Access Map

Universiti Malaya Medical Centre (UMMC)
Jln Profesor Diraja Ungku Aziz, Seksyen 13, 50603
Petaling Jaya, Selangor, Malaysia





Mahidol University
Faculty of Medicine Siriraj Hospital

Faculty of Medicine Siriraj Hospital, Mahidol University

Bangkok, Thailand



The Faculty of Medicine Siriraj Hospital, Mahidol University, established in 1889, is Thailand's oldest and most prestigious medical institution.

Hospitals Under the Faculty of Medicine Siriraj Hospital (FMSH)

The Faculty oversees four major hospitals, each contributing to comprehensive and specialized healthcare services:

- Siriraj Hospital
- Siriraj Piyamaharajkarun Hospital (SiPH)
- Golden Jubilee Medical Center
- Siriraj Academic Center of Geriatric Medicine

Clinical Service Capacity

The FMSH provides extensive healthcare services to Bangkok and its surrounding regions, with a total capacity of **2,526 beds, accommodating approximately 4.3 million outpatient visits and 120,000 inpatient admissions annually**. Its clinical infrastructure includes 16 intensive care units, 69 operating rooms. Supporting these services are 7,547 professional staff, 7,885 supporting personnel, and 928 academic staff, collectively reinforcing the Faculty's strengths in clinical care, training, and research excellence.

Key Accreditations and Recognitions

The FMSH holds numerous national and international accreditations that reflect its excellence as Thailand's leading academic medical institution. These recognitions affirm the Faculty's commitment to world-class standards in healthcare, education, and research.

Siriraj Institute of Clinical Research (SICRES)



SICRES is an academic clinical research institute established in 2020 under the Faculty of Medicine Siriraj Hospital.

Expertise covers:

- Clinical trial design and protocol development
- Feasibility assessments and site selection
- Regulatory and ethics submissions
- Full operational management of Phase I-IV clinical trials, observational studies, and bioequivalence studies

SICRES has been ISO 9001:2015 certified since 2021.

Research personnel

- 17 PIs specializing in Infectious Diseases
- 12 CRC
- 2 Clinical Research Nurses
- 13 Research Assistants
- 1 Clinical Research Associate
- 4 Investigator Product Specialists
- 2 Data specialists
- 2 Biostatisticians
- 2 Medical Writers

Infrastructures

- 32 standard hospital beds
- Refrigerators and ultralow temperature freezers
- Biosafety cabinets
- 24/7 temperature-controlled storage with remote alarm notification
- Private monitoring rooms for investigators, sponsors, and auditors
- Emergency equipment
- Backup power supply system
- 24-hour CCTV monitoring
- Synchronized clocks system for protocol compliance
- Dedicated patient areas, including a waiting area, examination rooms, and a treatment room

Infectious Diseases Clinical Trials achievements and collaborations

Types of interventions (2021-2025)

FY	2021	2022	2023	2024	2025
Vaccines	8	8	2	6	5
Drugs	4	7	6	11	7
Medical devices	1	2			

Trials by Phases (2021-2025)

FY	2021	2022	2023	2024	2025
Phase I		1	1		1
Phase II	3	3		2	
Phase III	10	8	6	9	10
Phase IV		1		4	1
Observational		4	1	2	

Trials by infectious diseases (2019-2023)

Diseases	Number of studies
Candidemia / invasive candidiasis	2
Chickenpox (Varicella)	1
COVID-19	20
Dengue fever	2
DTwP-HepB-Hib (diphtheria, tetanus, pertussis, hepatitis B, <i>Haemophilus influenzae</i> type b)	4
Gram-negative bacterial infections	5
HIV	9
HPV infection	1
Invasive fungal infections	2
Invasive pulmonary aspergillosis	3
Pneumococcal disease	1
Poliomyelitis	1
Rabies	2
Respiratory infections	2
RSV infection	6
Tuberculosis	1
Viral lung infections	2

Trials

- 64 IP, biologic, and medical device development studies in infectious diseases
- Studies span a broad range of viral, bacterial, and fungal pathogens, covering multiple therapeutic and preventive areas
- Include collaborations with Japanese industries (e.g., Shionogi & Co., Ltd. for infectious disease studies and Daiichi Sankyo for oncology studies).
- SICRES has participated in multi-country infectious disease trials (e.g., ReStore [Rezafungin], Scopio HR [Emsitrelvir for COVID-19], Paxlovid for COVID-19).
- SICRES has been inspected by the Thai FDA, USFDA, and the EMA.
- Ethical review timeline of 1-3 months
- Imports authorization for IP of 2-4 months.

Sample of manuscripts

- Immunogenicity and reactogenicity of fractional, heterologous primary COVID-19 vaccination schedules with BNT162b2 boosters in 5-11-year-old Thai children: A multicenter, prospective, double-blind, randomized control trial. *Vaccine*.2023, 41(40):5834-5840
- Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results. *PLoS One*.2023,18(7):e0288271
- Randomized Controlled Trial of the Immunogenicity and Safety of a Serum-Free Purified Vero Rabies Vaccine (PVRV-NG2) Using a Simulated Post-Exposure Zagreb Regimen With Human Rabies Immunoglobulin in Adults in Thailand, *Open Forum Infectious Diseases* 2024;11(11)
- Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials. *Lancet HIV*.2024, 11(2):e75-e85

Contact Information

Representative



Assoc. Prof. Dr. Pongsakorn Tantilipikorn, MD, PhD, FRCOT

Pongsakorn Tantilipikorn, MD, PhD, is an Associate Professor of Rhinology and Allergy and serves as Chair of the Center of Research Excellence in Allergy and Immunology at the Faculty of Medicine Siriraj Hospital. He is also the Assistant President for Research and Academic Affairs at Mahidol University.

He currently serves as the Director of the Siriraj Institute of Clinical Research (SICRES), following many years of dedicated involvement and support in leadership roles, including Vice Director, where he played a key role in strengthening the institute's clinical research capacity and strategic development. Dr. Pongsakorn received his Doctor of Medicine degree from Chiang Mai University in 1992, completed a postdoctoral fellowship in Rhinology at the University of Pennsylvania in 1999, and earned a PhD in Epidemiology and Biostatistics from Khon Kaen University in 2016. He is board certified in Otorhinolaryngology with subspecialty training in Facial Plastic and Reconstructive Surgery. His research interests include allergic rhinitis, rhinosinusitis, allergen immunotherapy, and endoscopic sinus surgery, along with advancing high-quality clinical research systems through his leadership at SICRES.

Focal Point

ARISE Secretariat:

Email: arise@jihhs.go.jp

Other Investigator

Emeritus Prof. Kulkanya Chokephaibulkit, M.D.


Assoc. Prof. Somruedee Chatsiricharoenkul, M.D.

Assist. Prof. Dr. Suvimol Niyomnaitam, M.D., MSCE, PhD

Address and Access Map

Faculty of Medicine Siriraj Hospital, Mahidol University

10th floor, Siriraj Medical Research Center (SiMR)
Faculty of Medicine Siriraj Hospital, Mahidol University
2 Wanglang Road, Siriraj, Bangkok Noi, Bangkok,
THAILAND, 10700 +66 (0) 2-414-1914





Corazon Locsin Montelibano Memorial Regional Hospital

Bacolod, Philippines



Founded in 1926 and classified as a tertiary-level government hospital with an authorized bed capacity of 1,000. It serves as the primary referral center for Bacolod City and the entire province of Negros Occidental with an estimated population of 3 million.

Over the decades, it has grown from a modest healthcare facility into a premier training institution for nurses and doctors with departments accredited by their respective societies.

In 2012, CLMMRH was declared a national site, and a marker was installed to recognize its historical significance and contribution to healthcare in the region.

It has also achieved and maintained ISO certifications for patient care management and residency training programs.

Clinical Trial Unit

- It was inaugurated and became operational in September 2024.
- Has partitioned spaces for consenting process, documentation and observation area
- Currently, clinical trial protocols are submitted to an external facility with a Level 3-accredited Ethics Committee for review and approval, or to the Single Joint Research Ethics Board (SJREB) of the Department of Health for multi-site trials within the country

Research personnel

- 4 experienced Investigators
- 1 Clinical Research Coordinators
- 1 Clinical Research Associate or Monitor
- 1 Data Manager
- 1 Biostatistician

Infrastructures

- IT services
- Secured records storage facility
- Investigational Product and sample storage
- Power back-up system
- Paper-based medical records

Distribution Breakdown of Clinical Trials from 2021 to 2025

Types of interventions

	2021	2022	2023	2024	2025
Vaccines	0	0	0	0	0
Drugs	0	1	0	0	0
Diagnostic test	1	0	0	0	0

Trials by Phases

	Phase1	Phase1/2	Phase2	Phase2/3	Phase3	Phase4
2021	0	0	1	0	0	0
2022	0	0	0	0	1	0
2023	0	0	0	0	0	0
2024	0	0	0	0	0	0
2025	0	0	0	0	0	0

Types of infectious disease

Diseases	Number of studies
COVID-19	2

Source: Philippine Health and Research Registry

Overview of Clinical Trials at CLMMRH

- Research conducted at the hospital primarily consists of investigator-initiated and non-interventional studies.
- Due to the Level 2 accreditation of its Research Ethics Review Committee, the involvement of the hospital in clinical trials is limited, but plans are underway to upgrade to Level 3 in the near future.
- Despite the limitations, its infectious disease specialists have actively led clinical trials at affiliated hospitals.
- Record of published trials show a higher number of oncology studies compared to those for infectious diseases
- With its strong connection with the Provincial Government and the Local Government Unit (LGU) recruitment for large-scale vaccine trials can be easily tapped.
- Key timelines:
EC review and approval – 3 months
Regulatory approval – 3 months

Publications

- Newborn Screening Long-Term Follow-Up Clinics (Continuity Clinics) in the Philippines during Covid-19 Pandemic: Continuing Patient Quality Care. *Int. J. Neonatal Screen.* 2023, 9(1), 2, <https://doi.org/10.3390/ijns9010002>
- Genomic Surveillance of Neisseria gonorrhoeae in the Philippines, 2013-2014. *Western Pac Surveill Response J.* 2021 Feb 26; 12(1):17-25. doi: [10.5365/wpsar.2020.11.1.005](https://doi.org/10.5365/wpsar.2020.11.1.005)
- Molecular characterization of rotavirus diarrhea among children aged under five years in the Philippines, 2013-2015. *Vaccine*, Volume 36, Issue 51, 14 December 2018, Pages 7888-7893. <https://doi.org/10.1016/j.vaccine.2018.08.046>

Source: <https://scholar.google.com/>

Contact Information

Representative



Dr. Ma. Luz Vicenta Guanzon
Chairperson
Research Committee
Specialization: Endocrinology

Focal Point


ARISE Secretariat
Email: arise@jihs.go.jp

Other Investigators

Dr. Carina Frayco (Infectious Disease)
Dr. Norman Cabaya (Oncology)
Dr. Ma. Luz Vicenta Guanzon (Endocrinology)
Dr. Hans Francis Ferraris (Pathology)

Address and Locator Map

Corazon Locsin Montelibano Memorial Regional Hospital
Lacson St., Bacolod, 6100 Negros Occidental,
Philippines



Source: <https://www.herdin.ph/index.php>



University of the Philippines Manila

Manila, Philippines



The University of the Philippines Manila (UPM) is the first campus and the birthplace of UP (established in 1908).

Within its grounds are the National Institute of Health (NIH), the Philippine General Hospital, the Medical and Allied Health colleges.

The Philippine General Hospital is a government- owned and controlled, public tertiary hospital and the largest national referral center. A teaching and training hospital with 19 clinical departments. Over 600,000 patients are seen and treated annually. It has a total bed capacity of 1,500.

In Oct 2025, the Philippine General Hospital earned the much-coveted ISO9001:2015 certificate for quality management standards. It received several accolades and recognitions. Some of the notable achievements are the Joint Commission International accreditation (2019) and the WHO Collaborating Center (2015).

National Clinical Trials and Translational Center (NCTTC)

NCTTC was formed in 2022 and one of the 15 institutes of NIH.

Functions:

- Supports local and international research networks and the conduct of multinational clinical trials
- Facilitates and standardizes processes and operations in clinical trial sites
- Provides training for the clinical trial team
- Assist publication and translation of research output into relevant health policies

■ Research personnel

- Principal Investigators for Infectious Diseases
- Clinical Research Coordinators
- Clinical Research Associates
- Data Managers
- Biostatisticians

■ Infrastructures

- In-hospital and outpatient clinical trial units (Pediatrics and Adult)
- IT services and Data Management system
- Laboratory equipped with freezers and refrigerators
- Secured storage for records, investigational product, and samples
- Power back-up

Distribution Breakdown of Clinical Trials from 2021 to 2025

Types of interventions

	2021	2022	2023	2024	2025
Vaccines	1	4	3	7	8
Drugs	4	0	4	2	1
Diagnostics	0	0	0	0	0

Trials by Phases

	Phase1	Phase1/2	Phase2	Phase2/3	Phase3	Phase4
2021	0	0	0	0	6	0
2022	0	0	2	1	0	1
2023	0	0	1	1	4	0
2024	0	0	2	2	5	0
2025	0	1	0	1	7	0

Trials by infectious diseases

Diseases	Number of studies
RSV	1
Covid-19	12
Dengue	3
Polio	2
Influenza	5
Hep B	3
Tuberculosis	4
Chikungunya	1
HPV	1
Bacterial Pneumonia	2

Sources: clinical trials.gov, Philippine Research Registry, and PUBMED

Overview of Clinical Trials at UP Manila

- Have had numerous past research collaborations with pharmaceutical companies, namely Shionogi, Takeda, Daiichi Sankyo, Chugai Pharmaceuticals, and among others.
- Participated in multiple large-scale clinical trials such as the WHO Solidarity Trial and RESTORE-IMI 2 Study.
- Have been previously inspected by US and Philippine FDA
- Ethical review timeline
 - Assuming no modifications
 - Full board – 60 calendar days
 - Expedited – 14 calendar days
- Import license for Investigational Product
 - Issued by the Philippine FDA
 - Timeline: 60 to 90 calendar days

Publications

- Repurposed Antiviral Drugs for Covid-19 – Interim WHO Solidarity Trial Results. *N Engl J Med* 2021 Feb 11; 384(6):497 – 511 DOI: [10.1056/NEJMoa2023184](https://doi.org/10.1056/NEJMoa2023184)
- Three-year Efficacy and Safety of Takeda's Dengue Vaccin Candidate (TAK-003). *Clin Infect Dis* 2022 Aug 24; 75(1):107 – 117 DOI: [10.1093/cid/ciab864](https://doi.org/10.1093/cid/ciab864)
- Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomized, double-blind placebo-controlled, phase 3 trial. *Lancet Respir Med* 2023 Dec; 11(12): 1075-1088. DOI: [10.1016/S2213-2600\(23\)00349-1](https://doi.org/10.1016/S2213-2600(23)00349-1)
- Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003); 4 to 5-year results from a phase 3, randomized, double-blind, placebo-controlled trial. *Lancet Glob Health* 2024 Feb 12(2):e257-e270 DOI: [10.1016/S2214-109X\(23\)00522-3](https://doi.org/10.1016/S2214-109X(23)00522-3)

Contact Information

Representative



Marissa Alejandria, MD, MSc

Director,
National Institute of Health
University of the Philippines Manila (UPM),
Philippines
Specialization: Adult Infectious Diseases

Focal Point

ARISE Secretariat

Email: arise@jih.s.go.jp

Other Investigators

Lia Aileen Palileo-Villanueva, MD, MSc (Internal Medicine)
Marimel G. Reyes-Pagcatipunan, MD (Pedia Infectious)
Lulu C. Bravo, MD (Pedia Infectious, Head of Vaccine Study Group at NIH)
Ralph Elvi Villalobos, MD (Pulmonary Medicine)
Maria L A Gonzales, MD (Pedia Infectious)

Address and Locator Map

University of the Philippines Manila (www.upm.edu.ph/)
 Philippine General Hospital (www.pgh.gov.ph/)

Taft Avenue, Ermita, Manila, 1000, Metro Manila,
Philippines

National Clinical Trials and Translational Center
 (<https://nih.upm.edu.ph/institute/national-clinical-trials-and-translation-center>)

9th Floor Henry Sy Sr.
Medical Sciences
Building at UP College
of Medicine, Pedro Gil.
St. Ermita, Manila



Camilo C. Roa Jr. MD (Pulmonary Medicine)
Anna Lisa Ong-Lim, MD (Pedia Infectious)
Regina P. Berba, MD (Adult Infectious)
Cecilia C. Maramba-Lazarte, MD (Infectious)
Aileen David Wang, MD (Pulmonary Medicine)



West Visayas State University

Iloilo, Philippines



Established in 1900, the university rose from humble beginnings as a teacher-training institution. Evolving across the decades and remaining rooted in its core values, it has grown into a renowned center of education and research.

It has six satellite campuses. The main campus consists of twelve distinct academic units, among which is the College of Medicine, notable for being the first in Western Visayas and the second state-owned medical school in the Philippines.

The university proudly holds an ISO certification, affirming its adherence to global standards and ensuring a top-tier learning environment for its students and faculty.

West Visayas State University Medical Center (WVSUMC)

Envisioned as “PGH of the South,” the WVSU Medical Center, a 300-bed tertiary hospital, functions as a training ground for the Colleges of Medicine, Nursing, and the Health Sciences. ISO 9001 certified since 2016. It offers accredited residency programs in Surgery, OB-GYNE, Internal Medicine, Pediatrics, Orthopedics, Psychiatry, Anesthesiology, Pathology, Radiology, and Family Medicine. It has an average of 13,000 admissions and 50,000 OPD consultations annually.

It operates independently of the Department of Health but follows policies that are consistent with the national healthcare standards.

■ Research personnel

- 10 experienced Investigators
- ※ Clinical Research Organizations (CROs) are contracted by sponsors to select the principal investigators tasked with directing the trial and forming the team.

■ Infrastructures

- IT services
- Secured records storage facility
- Investigational Product and sample storage
- Power back-up system
- Paper-based medical records

Distribution Breakdown of Clinical Trials from 2021 to 2025

Types of interventions

	2021	2022	2023	2024	2025
Vaccines	2	5	4	6	1
Drugs	2	2	3	2	0
Diagnostic test	0	0	0	0	0

Trials by Phases

	Phase1	Phase1/2	Phase2	Phase2/3	Phase3	Phase4
2021	0	0	0	2	3	0
2022	0	0	1	2	3	0
2023	2	0	0	1	4	0
2024	1	0	1	1	5	0
2025	0	0	0	0	1	0

Types of infectious disease

Diseases	Number of studies
COVID-19	8
Pneumonia	11
Influenza	5
Dengue	2
Hep B	1

Source: Philippine Health and Research Registry

Overview of Clinical Trials at WVSUMC

- Majority are initiated and sponsored by pharmaceutical companies from USA, UK, Japan, China, Sweden, Switzerland, and Austria.
- Trials conducted are predominantly in Phase 2 and 3, with vaccine trials increasing and surpassing drug trials in the post-covid period.
- Multi-country trials conducted in the past include ARCOV, EMPAREG, and the WHO Solidarity Trial.
- Key timelines:
 - EC review and approval – 3 months
 - Regulatory approval and importation authorization– 3 months
- Philippine FDA have conducted previous inspections

Publications

- Efficacy, safety, and immunogenicity of a booster a booster regimen of Ad26. CoV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomized, double-blind, placebo-controlled, phase 3 trial. *Lancet Infect Dis.* 2022 Dec; 22(12):1703-1715. DOI: [10.1016/S1473-3099\(22\)00506-0](https://doi.org/10.1016/S1473-3099(22)00506-0)
- Remdesivir and three other drugs for hospitalized patients with COVID-19: final results of the WHO Solitarity randomized trial and updated meta-analysis. *Lancet.* May 21;399(10339): 1941-1953. DOI: [10.1016/S0140-6736\(22\)00519-0](https://doi.org/10.1016/S0140-6736(22)00519-0)
- Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study. *Human Vaccines & Immunotherapeutics.* 2024 Vol.20, No. 1, 2408863. DOI: [10.1080/21645515.2024.2408863](https://doi.org/10.1080/21645515.2024.2408863)
- Safety ad immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1 dose-escalation study. *Human Vaccines & Immunotherapeutics.* 2024 Vol.20, No. 1, 2408863. DOI: [10.1080/21645515.2024.2408863](https://doi.org/10.1080/21645515.2024.2408863)

Source: PubMed

Contact Information

Representative



Dr. Joselito Villaruz
President
West Visayas State University
Specialization: Pediatrics

Focal Point

ARISE Secretariat
Email: arise@jih.s.go.jp

Other Investigators


Dr. Marie Grace Dawn T. Isidro (Pulmonary Medicine)
Dr. John Colacion (Pediatrics)
Dr. Eli John Berame (Pulmonary Medicine)
Dr. Roumilla Mendoza (Pediatrics)

Source: <https://www.herdin.ph/index.php>

Address and Locator Map

West Visayas State University and
West Visayas State University Medical Center


Luna St. Lapaz, Iloilo City 5000
Iloilo Philippines





Bach Mai Hospital

Hanoi, Vietnam



Located in Hanoi, Bach Mai Hospital (BMH), established in 1911, is the biggest comprehensive general hospital in Vietnam, serves as a special-level of health care system, with more than 4,500 medical staff and 3,600-bed capacity.

The hospital encompasses 8 institutions, 19 specialized centers, 14 Para-clinical/Clinical departments, and 1 Bach Mai Medical College.

Annually, this hospital welcomes more than 1,7 million outpatient visits and 215,000 inpatient visits.

As the largest teaching hospital in northern Vietnam, BMH has strong connections with other national hospitals and top medical universities nationwide.

Achievements

- In December 2025, it has inaugurated the second campus in Ninh Binh province, with 1000-bed capacity.
- With its comprehensive structure, BMH provides the highest level of treatment using high technique approach, professional application using complex intervention and AI application in cancer diagnosis, etc.
- The "**Bach Mai Procedure**" method has been registered in the world medical literature.
- Received Certificate of Accreditation ISO 15189:2007 for Biochemistry Department, Hematology and Blood Transfusion Center and Microbiology Department.

Infectious Diseases Clinical Research and Trials achievements and collaborations

Clinical Research and Trials

- Clinical Research Unit (CRU) was established in 2009 plays an important role in the management and coordination of clinical research.
- The CRU office is under the Bach Mai Institute for Training and Research in Medical and Pharmacy.
- Bach Mai Hospital strongly focuses on clinical research, conducting approximately 60 ~ 70 clinical research annually.
- Collaboration with international organizations and industries: Astra Zeneca, Novartis, Roche...

Infectious Diseases Clinical Research in collaboration with JIHS

- RT-LAMP study on rapid detection of avian influenza and other respiratory viral infections by reverse transcriptase loop-mediated isothermal amplification portable system in Bach Mai Hospital, Hanoi, Vietnam (2015 - 2016).
- Study for Ventilator-associated-pneumonia at Bach Mai Hospital in 2016 - 2017.
- Development of an AI-assisted bacteria identification online platform aimed at promoting digital transformation (DX) in the infectious diseases area in Vietnam in 2022 - 2023.

Contact Information

Representative



Assoc. Prof. Dao Xuan Co, M.D., Ph.D.

Director of Bach Mai Hospital

Associate Professor Dao Xuan Co, M.D., Ph.D. is the Director of Bach Mai Hospital. His specialty is in anesthesia and resuscitation.

During the COVID-19 pandemic, his expertise was crucial as the unit treated severe cases in collaboration with the Vietnamese Ministry of Health.

He is also the Vice-Rector at Vietnam National University – University of Medicine and Pharmacy.

Focal Point

ARISE Secretariat

Email: arise@jhs.go.jp

Address and Access Map

Bach Mai Hospital

No. 78 Giai Phong Street, Phuong Mai Ward, Hanoi, VIETNAM.





Hanoi Medical University

Hanoi, Vietnam



Established in 1902, Hanoi Medical University (HMU) is one of Vietnam's oldest and leading medical universities.

HMU comprises 1 university hospital, 1 university branch in the central region of Vietnam, 3 faculties, 43 departments, 2 schools, and over 2,300 staff members.

The university fosters collaborations with 97 hospitals and thousands of visiting lecturers in both Vietnam and international countries.

In 2016, HMU launched The Journal of Medical Research.

The HMU laboratory adheres to the ISO 15189:2012 certification standards.

Depending on the products and topics, the clinical trials are conducted in specialized departments. Each department has at least one Principal Investigator (PI).

Center of Clinical Pharmacology

Center of Clinical Pharmacology, established in 2013, is an autonomous research unit of HMU with the main missions: (1) Conduct clinical pharmacology research; (2) Implement clinical pharmacology activities at HMU hospital; (3) Provide training in clinical pharmacology; and (4) Consult and support governmental pharmaceutical management agencies.

Having collaborated with more than 20 pharmaceutical companies in both Vietnam and internationally.

GCP certificate from the Vietnam MOH in conducting:

- Bioequivalence studies;
- Clinical trials for chemical medicines;
- Clinical trials for *In vitro* devices;
- Clinical trials for biologics, vaccines;
- Clinical trials for herbal medicines.

Research personnel

- 45 Investigators for Phase 1 studies
- Up to 100 Investigators for Phase 3, 4 studies.

Infrastructures

- CRU for Phase 1,2: well-equipped with 60 beds; conduct up to 20 studies per year;
- CRU for Phase 3, 4: with four satellite sites;

Infectious Diseases Clinical Trials achievements and collaborations

Types of interventions (2021-2025)

	2021	2022	2023	2024	2025
Vaccines	3	2	2	2	4
Herbal Medicine	0	1	0	0	0
Chemical drug	1	1	1	1	1

Trials by Phases (2021-2025)

	Phase 1	Phase 2	Phase 2/3	Phase 3	Phase 4
2021	2	0	1	1	0
2022	1	1	1	2	0
2023	0	0	1	1	0
2024	0	0	1	2	0
2025	0	0	1	1	3

Sample of trials manuscripts

- Hồ NT, Hughes SG, **Ta VT**, Phan LT, Đỗ Q, Nguyễn TV, **Phạm ATV**, Thị Ngọc Đặng M, Nguyễn LV, Trịnh QV, Phạm HN, Chủ MV, Nguyễn TT, Lương QC, Tường Lê VT, Nguyễn TV, Trần LT, Thi Van Luu A, Nguyen AN, Nguyen XH. Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials. *Nat Commun.* 2024 May 14;15(1):4081. doi: 10.1038/s41467-024-47905-1. PMID: 38744844; PMCID: PMC11094049.
- Dinh Thiem V, **Van Anh PT**, Van Men C, Hung DT, Pollard AJ, Kamitani A, Tada Y, Fukuyama H, Iwasaki Y, Ariyasu M, Sonoyama T. A SARS-CoV-2 recombinant spike protein vaccine (S-268019-b) for COVID-19 prevention during the Omicron-dominant period: A phase 3, randomised, placebo-controlled clinical trial. *Vaccine.* 2024 Jun 20;42(17):3699-3709. doi: 10.1016/j.vaccine.2024.04.084. Epub 2024 May 10. PMID: 38734495.

Achievements

- Study ARCT-154-01 (ARCT-154)
Audited by Sponsor Arcturus (Sep 2022);
Inspected by PMDA (Japan) 21-25 Aug 2023.
Approved by EMA on December 12, 2024, with the brand name Kostaive.
- Study 2108T1221 (S217622)
Approved by PMDA on 22 Nov 2022 as brand name Xocova.
- Study 2126U0232 (S268019)
Audited by Sponsor Shionogi (Nov 2023);
Inspected by MHLW (Japan) 20-22 Dec 2023.
- Clinical trial application: 2 ~ 5 months.
- Import authorization for Investigational Product: 2 – 3 months.
- Past trials collaboration with Japanese organizations and industries: Shionogi; Daiichi Sankyo Propharma Co., Ltd.

Contact Information

Representative



Prof. Nguyen Huu Tu

Rector,

Professor of Anesthesia and Critical Care,
Hanoi Medical University;

Chairman of Department of Anesthesia
and Critical Care, Hanoi Medical University
and Hanoi Medical University Hospital.

Address and Access Map

Hanoi Medical University

No. 1 Ton That Tung street, Kim Lien Ward, Hanoi,
VIETNAM.




Focal Point

ARISE Secretariat:
Email: arise@jih.go.jp



University Medical Center Ho Chi Minh City

Ho Chi Minh City, Vietnam



BỆNH VIỆN ĐẠI HỌC Y DƯỢC
THÀNH PHỐ HỒ CHÍ MINH®
UNIVERSITY MEDICAL CENTER HCMC



Located in Ho Chi Minh City, the University Medical Center Ho Chi Minh City (UMC), established in 1994, is the first university hospital in Vietnam.

The main functions and responsibilities are (1) Medical examination and treatment; (2) Health professional training; and (3) Scientific research.

UMC is the second largest hospital in the south of Vietnam, comprising three facilities with a total of more than 3,800 staff members and a 1,000-bed capacity. The hospital serves more than 7,000 outpatient visits, 200 inpatient admissions daily.

The UMC Laboratory applies a quality management system that achieved ISO 15189:2012 certification in 2017 in all three areas of Biology, Chemistry, Hematology, and Microbiology (Immunology).

Clinical Research Unit

Clinical Research Unit (CRU) plays an important role in the management and coordination of clinical research in the hospital. Being part of the hospital system, the research unit is well-positioned to conduct studies using the hospital's infrastructure and facilities.

Number of clinical research and trials conducted per year: 15 – 18

Research personnel

- 22 Principal Investigators
- 15 Clinical Research Coordinators
- 17 Clinical Research Associate
- 02 Data manager
- 136 Others

Infrastructures

- Clinical Departments: Designated for receiving, consulting, and conducting clinical examinations specifically for research participants. Includes an injection room, procedure room, emergency room, storage area for research records, and a private restroom.
- Laboratory Department: Equipped for storing and preserving biological samples, with research-supporting equipment.
- Pharmacy Department: Equipped for storing medications and supporting research activities.

Infectious Diseases Clinical Research and Trials: Achievements and Collaborations

■ Infectious Diseases Clinical Research and Trials (2021-2025)

- Phase III trial of Proxalutamide (GT0918) in hospitalized COVID-19 patients.
- Surveillance of in vitro antibiotic susceptibility of Gram-negative bacteria isolated in Vietnam.
- Exploratory trial of oral ARV-1801 in combination with intravenous Ceftazidime or Meropenem for intensive phase therapy of Melioidosis in hospitalized patients.

■ Types of interventions (2021-2025)

	2021	2022	2023	2024	2025
Vaccines	0	0	0	0	0
Chemical drug	10	13	10	18	16

■ Trials by Phases (2021-2025)

	Phase 1	Phase 2	Phase 3	Phase 4
2021	0	0	9	1
2022	0	2	11	0
2023	0	0	8	2
2024	0	3	15	0
2025	0	2	14	0

■ Sample of trials manuscripts

- Dat TQ, Thong DQ, Nguyen DT, et al. Laparoscopic vs Open Distal Gastrectomy With D2 Lymphadenectomy for Clinical T4a Gastric Cancer: The UMC-UPPERGI-01 Randomized Clinical Trial. *JAMA Surg.* 2026;161(1):9–18. doi:10.1001/jamasurg.2025.4929

■ Achievements

- Achievements in Infectious Diseases Research and Trials
- UMC received the Vietnam Medical Achievement Award for its inter-hospital coordination and successful use of ECMO to save a critically ill pregnant woman and her baby.
- During the COVID-19 pandemic, the hospital served and saved many critically ill patients. Among 1,371 severe COVID-19 patients:
 - 158 patients requiring invasive mechanical ventilation were discharged.
 - 327 patients receiving high-flow nasal oxygen (HFNC) therapy were discharged.
 - UCICC successfully applied ECMO techniques to save many critically ill patients, including three pregnant women rescued from life-threatening conditions.
- Clinical trial approval time: institutional (1 month); national (2 months);
- Import authorization for Investigational Product: 2 – 3 months;
- Collaboration with Japanese organizations and industries: National Center for Child Health and Development, Kyushu University Hospital, Osaka University.

Contact Information

Representative



Assoc. Prof. Le Minh Khoi, M.D., FACC.

- Head, Science and Training Department
- Head, Echo Lab

Assoc. Prof. Le Minh Khoi received comprehensive medical training, including general practitioner and pediatric residency, as well as a medical doctorate (DAAD, Germany). His advanced training and fellowships in pediatric intensive care, pediatric and fetal cardiology, have been conducted across Europe, Asia, and the United States.

He has published widely in peer-review international journals, focusing on pediatric cardiology, critical care, COVID-19, genetics and digital health.

Furthermore, he has served as principal investigator and collaborator on numerous provincial-level and institutional research projects, demonstrating sustained interdisciplinary research capacity with substantial translational value for clinical practice and healthcare management.

Focal Point

ARISE Secretariat:
Email: arise@jhs.go.jp

Address and Access Map

University Medical Center Ho Chi Minh City

No. 215 Hong Bang Street, Cho Lon Ward,
Ho Chi Minh City, VIETNAM.

